NCT06367335View on ClinicalTrials.gov

Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer

CompletedOBSERVATIONAL
Enrollment

128

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

December 31, 2022

Conditions
DILI
Interventions
DRUG

Ribociclib, palbociclib, abemaciclib

evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI

Trial Locations (1)

20900

University of Milano-Bicocca,, Monza

All Listed Sponsors
lead

University of Milano Bicocca

OTHER